Your browser version may not work well with NCBI's Web applications. More information here...
1: J Biol Chem. 1992 Dec 5;267(34):24165-8.Click here to read Links

A member of the aldoketo reductase family confers methotrexate resistance in Leishmania.

Callahan HL, Beverley SM.

Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology, Boston, Massachusetts 02115.

Methotrexate (MTX)-resistant mutants of the parasitic protozoan Leishmania have been used as models for the mechanism and genetic basis of drug resistance in trypanosomatids and other cells. Three resistance mechanisms to MTX, a dihydrofolate reductase inhibitor, have been described in Leishmania: decreased uptake and accumulation of MTX via the folate/MTX transporter, amplification and overexpression of the dihydrofolate reductase-thymidylate synthase gene, and extrachromosomal amplification of H region DNA. We have now identified hmtxr as the H region gene conferring MTX resistance using a transfection-based approach. Data base searches show that the predicted HMTXr protein is related to members of the polyol dehydrogenase/carbonyl reductase family of aldoketo reductases, whose substrates include polyols, quinones, steroids, prostaglandins, fatty acids, and pterins. We therefore propose that HMTXr is also an oxidoreductase and suggest several biochemical mechanisms of resistance in Leishmania that could be exploited in the design of parasite-specific inhibitors.

PMID: 1339441 [PubMed - indexed for MEDLINE]

Related Articles

Patient Drug Information
  • Methotrexate (Rheumatrex®, Trexall®) Your doctor has ordered methotrexate to help treat your illness. Methotrexate comes as a tablet to take by mouth. Your doctor will tell you how often you should take methotrexate. The schedule depends on the condition y...
    » read more ...